Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Clinical development of two innovative pharmaceutical forms of leuprorelin acetate.

Geiges G, Schapperer E, Thyroff-Friesinger U, Engert ZV, Gravel P.

Ther Adv Urol. 2013 Feb;5(1):3-10. doi: 10.1177/1756287212471096.

2.

Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.

Gravel P, Samland D, Löffler M, Maier S, Panozzo M, Muenzberg M.

Adv Ther. 2013 Mar;30(3):271-85. doi: 10.1007/s12325-013-0010-y. Epub 2013 Mar 1.

PMID:
23460040
3.

Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.

Berges R, Bello U.

Curr Med Res Opin. 2006 Apr;22(4):649-55. Review.

PMID:
16684425
4.

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.

Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F.

Urol Int. 1998;60 Suppl 1:9-16; discussion 16-7.

PMID:
9563139
7.

Leuprorelin acetate in prostate cancer: a European update.

Persad R.

Int J Clin Pract. 2002 Jun;56(5):389-96. Review.

PMID:
12137449
8.

Treatment costs for advanced prostate cancer using LHRH agonists: a solid biodegradable leuprorelin implant versus other formulations.

Merseburger AS, Björk T, Whitehouse J, Meani D.

J Comp Eff Res. 2014 Dec 18:1-7. [Epub ahead of print]

9.

Therapeutic effects of leuprorelin microspheres in prostate cancer.

Lee M, Browneller R, Wu Z, Jung A, Ratanawong C, Sharifi R.

Adv Drug Deliv Rev. 1997 Oct 13;28(1):121-138.

PMID:
10837568
10.

Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.

Tunn UW, Wiedey K.

Prostate Cancer Prostatic Dis. 2009;12(1):83-7. doi: 10.1038/pcan.2008.52. Epub 2008 Nov 25.

PMID:
19030021
12.

Clinical pharmacokinetics of depot leuprorelin.

Periti P, Mazzei T, Mini E.

Clin Pharmacokinet. 2002;41(7):485-504. Review.

PMID:
12083977
13.

An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.

Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.

J Urol. 2000 Mar;163(3):838-44.

PMID:
10687989
14.

Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.

Schlegel PN, Kuzma P, Frick J, Farkas A, Gomahr A, Spitz I, Chertin B, Mack D, Jungwirth A, King P, Nash H, Bardin CW, Moo-Young A.

Urology. 2001 Oct;58(4):578-82.

PMID:
11597543
15.
16.

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.

Tunn UW, Gruca D, Bacher P.

Clin Interv Aging. 2013;8:457-64. doi: 10.2147/CIA.S27931. Epub 2013 Apr 26. Review.

17.

Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.

Crawford ED, Moul JW, Sartor O, Shore ND.

Expert Opin Drug Metab Toxicol. 2015 Sep;11(9):1465-74. doi: 10.1517/17425255.2015.1073711.

PMID:
26293510
18.

Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.

Schlegel PN; Histrelin Study Group.

J Urol. 2006 Apr;175(4):1353-8.

PMID:
16515997
19.

Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.

Iannazzo S, Pradelli L, Carsi M, Perachino M.

Value Health. 2011 Jan;14(1):80-9. doi: 10.1016/j.jval.2010.10.023.

PMID:
21211489
20.

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.

Garnick MB, Mottet N.

BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16.

PMID:
22093775
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk